Adaptive responses of the HER2+ SKBR-3 and BT474m1 cell lines to lapatinib and JQ1

SKBR-3 or BT474m1 HER2+ breast cancer cells were treated with either DMSO, 300nM lapatinib, 300nM JQ1, or lapatinib and JQ1 in combination for 48h. Overall design: 8 experimental samples

将SKBR-3与BT474m1型HER2阳性（HER2）乳腺癌细胞分为四组，分别采用二甲基亚砜（DMSO）、300nM拉帕替尼（lapatinib）、300nM JQ1，以及拉帕替尼与JQ1联合处理，处理时长均为48小时。实验设计概况：共包含8个实验样本。